Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Snap Inc (SNAP) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Snap Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? Snap Inc trades at $6.02 (market cap $10.98B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Snap Inc is far larger — about 6.1× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Snap Inc for 68 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

SNAPVIR
Market Cap
$10.98B$1.80B
Volume
53,140,1651,782,836
Sector
MediaHealth
52-Week High
$9.09$11.78
52-Week Low
$3.93$5.12
Typical Hold Time
68 Days0 Days
Enterprise Value
$12.54B$1.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Snap Inc

Snap Inc. (SNAP) trades at $6.49, down 0.76% on the day, showing continued volatility amid mixed signals. The stock maintains a bullish technical outlook with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, revenue growth continues (2025: $5.93B) while losses narrow (net margin improved to -7.77% in 2025), with recent enterprise partnerships for AR glasses driving optimism. Analyst consensus is mixed with 38% buy ratings but a $7.91 price target suggesting 22% upside potential from current levels.

Snap presents a turnaround story with improving operational metrics but significant execution risks. The company's expanding AR/enterprise initiatives and declining losses offer potential upside, though profitability remains elusive and debt levels are substantial. Regulatory pressures and intense social media competition create headwinds. The stock appears fairly valued with a P/S of 1.73, but requires sustained user growth and monetization improvements to justify higher multiples.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SNAP
0% Buy100% Sell
Avg holding period · 68 Days
VIR
51% Buy49% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Snap Inc

Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.

Read more on SNAP →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →